Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
GLP-1s may also reduce the risk of dementia in people with type 2 diabetes
You can rate severity levels and track patterns over time
Reductions in body weight were significantly greater with the LY3298176 1.5 mg, 4.5 mg and 10 mg doses versus placebo in MAD HS (LSM difference [95% CI]: -1.75 kg [-3.38, -0.12], -5.09 kg [-6.72, -3.46] and -4.61 kg [-6.21, -3.01], respectively) and doses of 10 mg and 15 mg had a relevant effect in T2DM patients (LSM difference [95% CI]: -2.62 kg [-3.79, -1.45] and -2.07 kg [-3.25, -0.88], respectively
Navigating Canadian Healthcare System Considerations Canadian patients face unique considerations when pursuing obesity treatment that differ from American or European contexts
But their off-label use for weight loss pushed them into the headlines
